Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population

被引:17
作者
Cai, Anping [1 ]
Li, Guang [1 ]
Chen, Jiyan [1 ]
Li, Xida [1 ]
Li, Liwen [1 ]
Zhou, Yingling [1 ]
机构
[1] Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Cardiovasc Inst, Dept Cardiol, Guangzhou 510080, Guangdong, Peoples R China
关键词
Coronary artery disease; Lipoprotein-associated phospholipase A2; Atherosclerosis; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE-A2; C-REACTIVE PROTEIN; HEART-DISEASE; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; A(2); ATHEROSCLEROSIS; DARAPLADIB; RISK; LYSOPHOSPHATIDYLCHOLINE;
D O I
10.1186/s12872-015-0001-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays complex and adverse roles on atherosclerosis. Current study was to investigate whether increased plasma Lp-PLA2 level is independently associated with the severity of coronary artery diseases (CAD). Methods: Totally 781 participants were enrolled and performed coronary angiography (CAG) to figure out the number of coronary artery stenosis. According to clinical presentation, electrocardiography, cardiac biomarker, and CAG result, participants were divided into control (excluded CAD), stable angina (SA), unstable angina (UA) and acute myocardial infarction (AMI) groups. Baseline characteristics were recorded. Statistical analyses were performed to evaluate the relationship between Lp-PLA2 level and CAD severity. Results: Plasma levels of Lp-PLA2 in control, SA, UA and AMI groups were 7.38(3.33-9.26) mu g/L, 5.94(2.89-8.55) mu g/L, 8.56(5.34-11.95) mu g/L and 8.68(5.56-13.27) mu g/L respectively (P < 0.001). After adjusted for age, gender, smoking, diabetes mellitus, hypertension, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), apoprotein A (apoA) and statins, Lp-PLA2 level was still independently associated with CAD severity, with odd ratio (OR) of 1.055 (AMI group versus control group, 95% confidence interval (CI) 1.021-1.090, P < 0.05). Additionally, the relationship between Lp-PLA2 level and the number of stenosis coronary artery was also assessed. Lp-PLA2 levels in control, single-vessel, and multiple-vessels stenosis groups were 7.38(3.33-9.26) mu g/L, 7.80 (4.05-10.76) mu g/L and 8.29(5.18-11.76) mu g/L respectively (P for trend < 0.001). After adjusted for age, gender, smoking, diabetes mellitus, hypertension, LDL-C and HDL-C, apoA and statins, Lp-PLA2 level remained independently associated with the number of coronary artery stenosis, with OR of 1.053 (multiple-vessels stenosis group versus control group, 95% CI 1.025-1.069, P < 0.05). Conclusion: Increased Lp-PLA2 level is independently associated with CAD severity, and Lp-PLA2 level may be used to discriminate those who are at increased risk of cardiovascular events.
引用
收藏
页数:5
相关论文
共 25 条
[1]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[2]   Peripheral artery disease, biomarkers, and darapladib [J].
Berger, Jeffrey S. ;
Ballantyne, Christie M. ;
Davidson, Michael H. ;
Johnson, Joel L. ;
Tarka, Elizabeth A. ;
Lawrence, Denise ;
Trivedi, Trupti ;
Zalewski, Andrew ;
Mohler, Emile R., III .
AMERICAN HEART JOURNAL, 2011, 161 (05) :972-978
[3]  
Cai AP, 2013, DIS MARKERS, V34, P323, DOI [10.3233/DMA-130976, 10.1155/2013/432136]
[4]   Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity in Japanese Dyslipidemic Patients, With Exploratory Analysis of a PLA2G7 Gene Polymorphism of Val279Phe [J].
Daida, Hiroyuki ;
Iwase, Takayuki ;
Yagi, Shigeru ;
Ando, Hidekazu ;
Nakajima, Hiromu .
CIRCULATION JOURNAL, 2013, 77 (06) :1518-1525
[5]   Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: The Rancho Bernardo study [J].
Daniels, Lori B. ;
Laughlin, Gall A. ;
Sarno, Mark J. ;
Bettencourt, Ricki ;
Wolfert, Robert L. ;
Barrett-Connor, Elizabeth .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (09) :913-919
[6]   Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines [J].
Davidson, Michael H. ;
Corson, Marshall A. ;
Alberts, Mark J. ;
Anderson, Jeffrey L. ;
Gorelick, Philip B. ;
Jones, Peter H. ;
Lerman, Amir ;
McConnell, Joseph P. ;
Weintraub, Howard S. .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A) :51F-57F
[7]   Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community [J].
Gerber, Yariv ;
McConnell, Joseph P. ;
Jaffe, Allan S. ;
Weston, Susan A. ;
Killian, Jill M. ;
Roger, Veronique L. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (11) :2517-2522
[8]  
Goff DC Jr, 2014, CIRCULATION, V129, pS49, DOI [10.1016/j.jacc.2013.11.005, 10.1161/01.cir.0000437741.48606.98]
[9]   The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice [J].
Hu, Miao-miao ;
Zhang, Jie ;
Wang, Wen-yi ;
Wu, Wen-yu ;
Ma, Yan-ling ;
Chen, Wei-hai ;
Wang, Yi-ping .
ACTA PHARMACOLOGICA SINICA, 2011, 32 (10) :1253-1258
[10]   Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus:: Relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment [J].
Iwase, Masanori ;
Sonoki, Kazuo ;
Sasaki, Nobuhiro ;
Ohdo, Shigehiro ;
Higuchi, Shun ;
Hattori, Hiroaki ;
Iida, Mitsuo .
ATHEROSCLEROSIS, 2008, 196 (02) :931-936